Management of Glaucoma As a Neurodegenerative Disease
- 1 April 2017
- journal article
- review article
- Published by Informa UK Limited in Neurodegenerative Disease Management
- Vol. 7 (2), 157-172
- https://doi.org/10.2217/nmt-2017-0004
Abstract
Glaucoma is a neurodegenerative disease with an estimated prevalence of 60 million people, and the most common cause of irreversible blindness worldwide. The mainstay of treatment has been aimed at lowering intraocular pressure, currently the only modifiable risk factor. Unfortunately, despite adequate pressure control, many patients go on to suffer irreversible visual loss. We first briefly examine currently established intraocular pressure lowering-treatments, with a discussion of their roles in neuroprotection as demonstrated by both animal and clinical studies. The review then examines currently available intraocular pressure independent agents that have shown promise for possessing neuroprotective effects in the management of glaucoma. Finally, we explore potential future treatments such as immune-modulation, stem cell therapy and neural regeneration as they may provide further protection against the neurodegenerative processes involved in glaucomatous optic neuropathy.Keywords
This publication has 140 references indexed in Scilit:
- Clinical Evidence for Neuroprotection in GlaucomaAmerican Journal of Ophthalmology, 2011
- Mitochondria-targeted antioxidant peptide SS31 attenuates high glucose-induced injury on human retinal endothelial cellsBiochemical and Biophysical Research Communications, 2011
- Distal axonopathy with structural persistence in glaucomatous neurodegenerationProceedings of the National Academy of Sciences of the United States of America, 2010
- Regulation of mTOR Complex 1 (mTORC1) by Raptor Ser863 and Multisite PhosphorylationPublished by Elsevier BV ,2010
- Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucomaProceedings of the National Academy of Sciences of the United States of America, 2009
- A Comparison of the Long-Term Effects of Dorzolamide 2% and Brinzolamide 1%, Each Added to Timolol 0.5%, on Retrobulbar Hemodynamics and Intraocular Pressure in Open-Angle Glaucoma PatientsJournal of Ocular Pharmacology and Therapeutics, 2009
- Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivoExperimental Eye Research, 2009
- Update on the Mechanism of Action of Topical Prostaglandins for Intraocular Pressure ReductionSurvey of Ophthalmology, 2008
- Targeting amyloid-β in glaucoma treatmentProceedings of the National Academy of Sciences of the United States of America, 2007
- Oxidative stress in glaucomatous neurodegeneration: Mechanisms and consequencesProgress in Retinal and Eye Research, 2006